Dave Lennon, former president of Novartis Gene Therapies
September 21, 2021 03:29 PM EDTUpdated September 22, 06:31 AM
People
Bioregnum

So what hap­pened with No­var­tis Gene Ther­a­pies? Here's your an­swer

Over the last cou­ple of days it’s be­come clear that the gene ther­a­py di­vi­sion at No­var­tis has qui­et­ly un­der­gone a ma­jor re­or­ga­ni­za­tion. We learned on …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Trump says he'll sign or­der on 'most-fa­vored na­tion' drug price plans Mon­day

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times